Functionalized carbon quantum dot as well as preparation method and application thereof

By modifying the strong chelating agent ligand onto the carbon quantum dots, a new type of nuclide detergent is formed, which solves the problems of low nuclide detergent efficiency and transdermal absorption in the prior art, real-time monitoring and waste liquid treatment are achieved Convenient, significantly improving the safety and efficiency of nuclear emergency technology.

CN119039981AActive Publication Date: 2024-11-29SUZHOU UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411009506.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-29
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

The detergent used in existing nuclear emergency technology to remove radionuclides on the body surface is limited in efficiency, and it is easy to lead to transdermal absorption and internal contamination of the nuclides, and the decontamination effect cannot be monitored in real time, resulting in difficulty in handling waste liquids.

Method used

Using functionalized carbon quantum dot materials, chelating agent ligands with strong chelation ability to uranium are modified onto carbon quantum dots to form a new chelating agent, which prevents transdermal absorption by agglomeration after binding to nuclides and is quenched by fluorescence. Realize real-time monitoring and control of the cleaning process.

Benefits of technology

It effectively improves the surface decontamination efficiency of nuclides, avoids transdermal absorption of nuclides, achieves convenience of real-time monitoring and waste liquid treatment, and significantly improves the safety and efficiency of nuclear emergency technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039981A_ABST
    Figure CN119039981A_ABST
Patent Text Reader

Abstract

The invention discloses a functionalized carbon quantum dot as well as a preparation method and application thereof. The functionalized carbon quantum dot has a structural formula as shown in a formula (1) or a formula (2): # imgabs0 #, and is formed by grafting a carbon quantum dot and a chelating agent ligand. The functionalized carbon quantum dot material can effectively chelate nuclides and improve the body surface decontamination efficiency of the nuclides; the functionalized carbon quantum dot material is combined with nuclide and then agglomerated, so that the particle size is increased, transdermal absorption can be prevented, and internal pollution caused by blood circulation after permeating into skin is avoided; after the functionalized carbon quantum dot material is complexed with the nuclide, the fluorescence intensity is gradually quenched, the change of the nuclide content can be monitored in real time in the decontamination process, and decontamination and monitoring integration is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of chemical synthesis, and in particular to functionalized carbon quantum dots and a preparation method and application thereof. Background Art

[0002] The rise of the nuclear energy industry today will inevitably lead to nuclear safety issues. The radioactive waste generated by nuclear energy, the recycling process of nuclear fuel, and nuclear accidents in large nuclear facilities will bring nuclear risks to workers with potential occupational exposure risks and ordinary people without protective measures. We cannot solve this nuclear risk with conventional safeguards. Therefore, while developing nuclear energy, we need to develop nuclear emergency technology to protect the development of nuclear energy. Among them, for the surface contamination caused by radioactive elements leaked in nuclear accidents, the radioactive nuclide surface decontamination agent in nuclear emergency technology can effectively remove surface radioactive contamination, block the deposition of radioactive nuclides on the surface, and reduce persistent hazards.

[0003] Based on the contamination of radionuclides on the human body surface, my country's GBZ / T 216-2009 "Specifications for the Treatment of Radionuclides on the Human Body Surface" mentions that for the decontamination of plutonium and trans-plutonium elements, it is recommended to use 1% DTPA or 10% EDTA solution for treatment, and for uranium contamination, 1.4% bicarbonate solution can be used for decontamination. The World Health Organization (WHO) and the International Atomic Agency (IAEA) mainly recommend the use of warm water or soapy water for the decontamination of nuclides on intact skin, and also mention the use of potassium permanganate or low-concentration bleach for decontamination. Among the above-mentioned products for the decontamination of nuclides on the body surface, the decontamination principle of water, soapy water or potassium permanganate is mainly physical action, and the surface nuclides are removed by flushing, and the delayed decontamination effect is very limited. In addition, potassium permanganate and bleach are skin irritants and can easily cause skin damage.

[0004] By adding chelating agents such as DTPA and EDTA, the chelating agents can effectively chelate surface nuclides while physically flushing, which can significantly improve the decontamination effect. Based on this, in order to further improve the decontamination effect, researchers have applied organic phosphate chelating agents with stronger affinity for actinides to surface nuclides decontamination. Hydroxyethyl diphosphonic acid (HEDP) has a strong chelating ability for plutonium and uranium, and can effectively remove plutonium and uranium from the body surface. However, studies have found that the complexes of HEDP and actinides easily penetrate the skin. After HEDP and uranium or plutonium acted together on the skin surface of rats for 24 hours, about 23.4% of uranium or 17.9% of plutonium entered the dermis, and then entered the blood circulation to cause internal contamination.

[0005] Exogenous substances can enter the dermis through the cells and intercellular spaces of the epidermis, hair follicles and sweat glands. Their skin absorption characteristics are related to the physical and chemical properties of the exogenous substances, such as solubility, particle size, shape, and affinity with the skin. Studies have found that nanoparticles with a particle size greater than 40nm cannot penetrate the stratum corneum of the skin, while particles with a particle size less than 40nm can enter the dermis through intercellular spaces, hair follicles, and sweat glands. Therefore, the problem of transdermal absorption of actinides caused by disinfectants may be avoided by increasing the particle size of the chelating agent. Based on this, the French Institute for Radiation Protection and Nuclear Safety incorporated calixarene into paraffin oil with ionic surfactants to obtain calixarene nanoemulsions. The nanoemulsion has a particle size of 150-200nm and can chelate with uranium when in contact with uranium solution. The size of the material can effectively prevent skin penetration, showing excellent application prospects for surface nuclide decontamination. However, its particle size and limited chelation sites on the surface prevent it from fully chelating uranium. In addition, calixarene has certain hepatotoxicity, which limits the application of this type of chelating agent. In addition, in actual nuclear emergency scenarios, conventional decontamination agents cannot monitor the decontamination effect, which can easily lead to excessive use of decontamination agents and produce a large amount of radioactive waste liquid. There are major problems in the post-treatment of these radioactive waste liquids, which brings inconvenience to nuclear emergency treatment. Therefore, scientific researchers are forced to develop new low-toxic and high-efficiency radionuclide surface decontamination fluids.

[0006] In order to solve the above problems, the present invention proposes to apply functionalized carbon quantum dot materials to the field of nuclide decontamination. Carbon quantum dot materials (CQDs) are zero-dimensional carbon nanomaterials with significant fluorescence properties. They have good biocompatibility, excellent water solubility and chemical stability, and are widely used in environmental detection, cancer treatment, antibacterial and other aspects. In the present invention, Cm-3,2-HOPO with strong uranium chelating ability is screened out, and Cm-3,2-HOPO is modified on carbon quantum dots to obtain Cm-HOPO-CQDs with uniform particle size. Studies have found that Cm-HOPO-CQDs aggregate after combining with nuclides, and the particle size aggregates from 2-3nm to about 1000nm. While effectively chelating nuclides, the transdermal absorption of the complex is prevented to avoid internal contamination; in addition, the fluorescence intensity of Cm-HOPO-CQDs is gradually quenched after complexing with nuclides. During the decontamination process, the changes in the nuclide content can be monitored in real time, so as to achieve integrated decontamination monitoring. Subsequently, by matching the uranium coordination pattern, a new type of phosphate ligand DPC with strong chelating ability was designed and modified onto the carbon quantum dots to obtain DPC-CQDs with uniform particle size. Similarly, the material aggregated and underwent fluorescence quenching after binding with radionuclide ions, achieving skin absorption resistance and real-time fluorescence monitoring while removing contaminants. This shows that functionalized carbon quantum dot materials have a certain universality in surface decontamination, absorption resistance and real-time monitoring. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a functionalized carbon quantum dot and a preparation method and application thereof, wherein a chelating agent ligand with a nuclide decontamination function is modified onto the carbon quantum dots to obtain a new chelating agent with uniform particle size, which aggregates after combining with the nuclide, and the particle size aggregates from 2-3nm to about 1000nm, effectively chelating the nuclide while preventing the transdermal absorption of the complex to avoid internal contamination; after the new chelating agent is complexed with the nuclide, the fluorescence intensity is gradually quenched, and the changes in the nuclide content can be monitored in real time during the decontamination process, so as to achieve integrated decontamination and monitoring.

[0008] In order to solve the above technical problems, the present invention provides a functionalized carbon quantum dot having a structural formula of formula (1) or formula (2):

[0009]

[0010] The second aspect of the present invention provides a method for preparing the functionalized carbon quantum dots described in the first aspect, which is prepared by amidation of the amino groups on the surface of the carbon quantum dots (CQDs) of formula (3) with the carboxyl groups of the chelating agent ligands, wherein the chelating agent ligands are compounds of formula (4) (Cm-3,2-HOPO) or compounds of formula (5) (DPC), and the reaction route is:

[0011]

[0012] The present invention grafts CQDs with chelating agent ligands Cm-3,2-HOPO or DPC to obtain new chelating agents Cm-HOPO-CQDs and DPC-CQDs, respectively. The new chelating agent aggregates after binding with the nuclide, and the particle size aggregates from 2-3nm to about 1000nm. While effectively chelating the nuclide to achieve nuclide surface decontamination, it prevents the transdermal absorption of the complex, avoids penetration into the skin, and causes internal pollution after entering the blood circulation. In addition, the fluorescence intensity of the new chelating agent is gradually quenched after complexing with the nuclide. Based on the fluorescence quenching experiment, the change of the nuclide content can be monitored in real time during the decontamination process, so as to achieve integrated decontamination monitoring; the chelating agent functionalized CQDs material aggregates and precipitates after binding with the nuclide, and can be monitored in real time, so the amount of decontamination agent can be effectively controlled, and the aggregates in the waste liquid can be collected as solid waste by filtration, which effectively alleviates the pressure of waste liquid post-treatment and has strong nuclear emergency response.

[0013] Furthermore, the specific steps of the grafting are: adding an activator and a condensing agent to a chelating agent ligand solution under ice bath conditions, transferring to a constant temperature of 20-35° C., adding a carbon quantum dot solution, and reacting to obtain functionalized carbon quantum dots;

[0014] Wherein, when the chelating agent ligand is a compound of formula (4), the reaction conditions are: adding a catalyst palladium / carbon to remove the benzyl group on the hydroxypyridone under a hydrogen atmosphere.

[0015] Furthermore, the mass ratio of the chelating agent ligand to the carbon quantum dots is 1:(1-3).

[0016] Furthermore, the solvent of the carbon quantum dot solution is deionized water.

[0017] Furthermore, when the chelating agent ligand is a compound of formula (4), the solvent of the chelating agent ligand solution is N,N-dimethylformamide (DMF) or methanol, and the constant temperature condition is an oil bath. After the reaction is completed, palladium / carbon (Pd / C) is filtered and separated, and most of the water and DMF in the filtrate are removed by rotary evaporation. The remaining mixture is diluted with water and filtered. The filtrate is concentrated again and dialyzed for 2-3 days. The purified solution is concentrated and freeze-dried to obtain brown powder Cm-HOPO-CQDs.

[0018] Furthermore, when the chelating agent ligand is a compound of formula (5), the solvent of the chelating agent ligand solution is deionized water. After the reaction is completed, the solution is dialyzed, concentrated, and freeze-dried to obtain brown powder DPC-CQDs.

[0019] Furthermore, the activator is one or more of N-hydroxysuccinimide (NHS), 2,2-dihydroxymethylpropionic acid (DMPA), and 1-hydroxybenzotriazole (HOBT).

[0020] Furthermore, the condensing agent is one or more of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), N,N-dicyclohexylcarbodiimide (DCC), and N,N'-diisopropylcarbodiimide (DIC).

[0021] Furthermore, the preparation method of the carbon quantum dots is: mixing a citric acid monohydrate (CA) solution with a branched polyethyleneimine solution, and reacting them at 160-200° C. to obtain the carbon quantum dots.

[0022] Furthermore, the solvents of the citric acid monohydrate solution and the branched polyethyleneimine solution are both water, the branched polyethyleneimine solution is heated to 40-60° C. and stirred to dissolve, and after the reaction, it is dialyzed, concentrated, and freeze-dried to form yellow powder carbon quantum dots.

[0023] The preparation method of the chelating agent ligand compound of formula (4) of the present invention has been disclosed in patent CN 106928132 A, which will not be described in detail here.

[0024] Furthermore, the preparation method of the compound of formula (5) is:

[0025] S1, adding ethyl bromoacetate and a catalyst to an organic solution of the compound of formula (6), reacting in an ice-water bath to obtain an intermediate of formula (7), the reaction route is:

[0026]

[0027] S2. The intermediate of formula (7) reacts with an acid in a boiling water bath to obtain the compound of formula (5).

[0028] Furthermore, the catalyst is one or more of sodium bis(trimethylsilyl)amide, sodium methoxide, sodium ethoxide, and quaternary ammonium base.

[0029] Furthermore, the solvent of the organic solution of the compound of formula (6) is tetrahydrofuran (THF) and / or DMF.

[0030] Furthermore, the acid is hydrochloric acid or glacial acetic acid.

[0031] Furthermore, after the reaction of S1 is completed, the solvent is distilled off under reduced pressure, dichloromethane (DCM) and / or chloroform is added to dissolve, the insoluble matter is removed by suction, the filtrate is collected and concentrated, and the product is purified by column chromatography (gradually increasing the polarity from pure EA to EA / MeOH=10 / 1).

[0032] The third aspect of the present invention provides the use of the functionalized carbon quantum dots described in the first aspect in body surface radionuclide decontamination.

[0033] Furthermore, the nuclide is one or more of the actinide elements uranium, thorium, neptunium, plutonium, americium, the lanthanide elements europium, cerium, lanthanum, and the heavy metals mercury, chromium, and lead.

[0034] Beneficial effects of the present invention:

[0035] The functionalized carbon quantum dot material of the present invention can effectively chelate nuclides and improve the efficiency of surface disinfection of nuclides; after the functionalized carbon quantum dot material is combined with the nuclides, it agglomerates to increase the particle size, which can prevent transdermal absorption, avoid penetrating into the skin, and cause internal pollution after entering the blood circulation. After the functionalized carbon quantum dot material of the present invention is complexed with the nuclides, the fluorescence intensity is gradually quenched. During the disinfection process, the change of the nuclide content can be monitored in real time, and the disinfection monitoring can be integrated; the chelating agent functionalized carbon quantum dot material agglomerates and precipitates after combining with the nuclides, and can be monitored in real time, which can effectively control the amount of disinfectant used, and the aggregates in the waste liquid can be collected as solid waste by filtration, which effectively alleviates the pressure of waste liquid post-treatment and has strong nuclear emergency response. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 is a hydrogen nuclear magnetic resonance spectrum of the bisphosphate ethyl ester intermediate of the present invention;

[0037] Figure 2 is a hydrogen nuclear magnetic resonance spectrum of the organic bisphosphate ligand of the present invention;

[0038] Figure 3 is the particle size distribution diagram of CQDs, Cm-HOPO-CQDs and DPC-CQDs;

[0039] Figure 4 It is the infrared spectra of CQDs, HOPO, Cm-HOPO-CQDs, DPC, and DPC-CQDs;

[0040] Figure 5 In the figure, (a) is a schematic diagram of the aggregation of Cm-HOPO-CQDs and DPC-CQDs with uranium, (b) is the change in particle size of Cm-HOPO-CQDs before and after complexation with uranyl ions, and (c) is the change in particle size of DPC-CQDs before and after complexation with uranyl ions;

[0041] Figure 6 is the change in fluorescence intensity of Cm-HOPO-CQDs and DPC-CQDs after they interact with uranium;

[0042] Figure 7 In the figure, (a) is a schematic diagram of the decontamination of uranium on the surface of pig skin by a decontamination agent; (b) are diagrams of the decontamination efficiency of DTPA, Cm-HOPO-CQDs and DPC-CQDs on the surface of pig skin;

[0043] Figure 8 In the figure, (a) and (b) are the size and morphology of Cm-HOPO-CQDs before and after uranium decontamination, (c) and (d) are the size and morphology of DPC-CQDs before and after uranium decontamination, (e) is a schematic diagram of the absorption resistance test, and (f) is the uranium content remaining on the skin surface after uranium, uranium and disinfectant (DTPA, Cm-HOPO-CQDs or DPC-CQDs) co-contaminate the skin for two hours;

[0044] Fig. 9 In the figure, (a) and (b) are the fluorescence intensity changes of Cm-HOPO-CQDs and DPC-CQDs solutions during uranium decontamination, respectively. DETAILED DESCRIPTION

[0045] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0046] Example 1

[0047] This embodiment relates to a method for preparing functionalized carbon quantum dots, comprising the following steps:

[0048] (1) Synthesis of CQDs of compound (3)

[0049] Weigh 0.16g CA into a 15mL centrifuge tube, add 11mL water and ultrasonically dissolve to obtain CA solution for use; weigh 0.06g BPEI into a beaker, add 1mL water, place on a stirrer, heat to 50℃ to dissolve, add to CA solution, mix thoroughly and transfer to a 20mL Teflon-lined reactor, heat in an oven at 180℃ for 6 hours and then cool to room temperature, take out the reaction solution and dialyze and concentrate it, and finally freeze-dry it into yellow powder CQDs.

[0050] (2) Synthesis of compound Cm-3,2-HOPO of formula (4)

[0051] Weigh 11.1g of 2,3-dihydroxypyridine into a reaction flask, add 83.5g of ethyl bromoacetate, pass N2 below the reaction liquid surface and stir for 1h, then reflux at 150°C for 24h under N2 protection. After the reaction is completed, remove the reaction flask from the oil bath, cool to room temperature, precipitate the solid, then filter the reaction solution, wash the solid with acetone 3-5 times, and recrystallize it with ethanol. After drying in a vacuum drying oven for 24h, an off-white intermediate product is obtained. The intermediate product is dissolved in 300mL of 90% methanol aqueous solution, and then the pH of the solution is adjusted to about 12 with NaOH aqueous solution, and then 25g of benzyl chloride is added. Under the condition of pH=12, reflux at 80°C for 8h. During the reaction, the solution slowly changes from colorless to reddish brown. After the reaction is completed, the reaction is cooled to room temperature and the methanol in the reaction solution is removed by rotary evaporation. Add 100 mL of H2O to the remaining reaction solution, extract the aqueous solution with dichloromethane, use 50 mL each time, extract twice, adjust the reaction solution to pH = 1 with dilute hydrochloric acid until a precipitate is formed. Filter the precipitate and dry it in a vacuum oven for 24 hours. Recrystallize it with methanol and dry it to obtain white needle-shaped crystals of Cm-3,2-HOPO.

[0052] (3) Synthesis of compound DPC of formula (5)

[0053] After evacuating a 25mL three-necked flask and passing N2, 490mg (1.70mmol, 1eq) tetraethyl methylene diphosphate and 10mL anhydrous THF were added to the flask. 1.10g (40% in THF, 2.75mmol, 1.6eq) sodium bis(trimethylsilyl)amide was slowly injected under an ice-water bath, and the solution turned light brown. Then 710mg ethyl bromoacetate (4.25mmol, 2.5eq) was injected, and the solution turned into a red suspension. The reaction was stirred at about 0°C. The reaction was monitored by thin layer chromatography (EA / MeOH=10 / 1) during the reaction. The reaction was completed after stirring for about 22h. The solvent was removed by vacuum distillation to obtain a yellow viscous substance, which was dissolved by adding DCM, and the insoluble matter was removed by suction filtration. The filtrate was collected and concentrated, and the column chromatography separation (gradually increasing the polarity from pure EA to EA / MeOH=10 / 1) obtained a light yellow oily product bisphosphate ethyl ester intermediate 460mg, with a yield of about 73%. The results of H NMR spectra are shown in Figure 1 , specifically: 1 H NMR (400MHz, CDCl3): δ4.18 (m, 10H), 3.11 (tt, J = 16Hz, 4.4Hz, 1H), 6.72 (td, J = 10.4Hz, 4Hz, 2H), 1.33 (td, J = 4.4Hz, 1.6Hz, 12H), 1.28 (t, J = 4.8Hz, 3H).

[0054] Take 500 mg (1.34 mmol) of bisphosphonate ethyl ester intermediate and add it to a round-bottom flask, add 30 mL of hydrochloric acid solution (1M), reflux for 24 hours, and remove the solvent by vacuum distillation to obtain a colorless transparent liquid. After vacuum drying, 300 mg of white solid organic bisphosphonic acid ligand (DPC) is obtained, with a yield of about 96%. The results of H NMR test are shown in Figure 2 , specifically: 1 H NMR (400 MHz, D2O): δ2.81 (m, 3H); m / z calculated based on LC-MS [MH] results was 232.96, and the experimental result was 232.93.

[0055] (4) Synthesis of Cm-HOPO-CQDs from formula (1)

[0056] Take 0.4g Cm-3,2-HOPO ligand and dissolve it in 20mL DMF, stir it in an ice bath for 30min, add 0.38g EDC and 0.23g NHS, and continue to ice bath for 30min, transfer it to a 30℃ oil bath and stir it at constant temperature for 1h for standby use; dissolve 0.6g CQDs in 10mL deionized water and add it dropwise to the above solution, react for 24h, add 40mg Pd / C (10%), and stir it for 6h under hydrogen atmosphere. Pd / C is separated by filtration, most of the water and DMF in the filtrate are removed by rotary evaporation, the remaining mixture is diluted with water and filtered, the filtrate is concentrated again and dialyzed for 2-3 days, and finally the purified solution is concentrated and freeze-dried to obtain brown powder Cm-HOPO-CQDs.

[0057] (5) Synthesis of DPC-CQDs using formula (2)

[0058] 0.33 g DPC was dissolved in 20 mL deionized water and stirred in an ice bath for 0.5 h. Subsequently, 0.34 g EDC and 0.2 g NHS were added. After 30 min, the reaction was transferred to room temperature and reacted for 1 h. 0.55 g CQDs were dissolved in 10 mL deionized water and added to the reaction solution. The reaction lasted for 1 day, then dialyzed, concentrated, and freeze-dried to form brown powder DPC-CQDs.

[0059] Test Case

[0060] (1) Characterization of Cm-HOPO-CQDs and DPC-CQDs

[0061] Figure 3 The particle size distribution diagram of CQDs, Cm-HOPO-CQDs and DPC-CQDs shows that the average particle size of CQDs is 1.9 nm (PDI = 0.014). After functional modification of DPC and Cm-HOPO, the particle size increases to about 2-4 nm. This is because the overall particle size increases after DPC and Cm-HOPO are grafted onto the surface of CQDs.

[0062] Figure 4 The Fourier transform infrared spectra of CQDs, HOPO of formula (4), DPC of formula (5), Cm-HOPO-CQDs, and DPC-CQDs. In the infrared spectrum of CQDs, 3400 cm -1 is the stretching vibration peak of NH bond, 1650cm -1 The NH bond bending vibration peak is at 1434 cm, indicating that the molecular structure of PEI exists on the surface of CQDs in the form of amino groups during the synthesis of CQDs. After DPC modified CQDs, the infrared spectrum of DPC-CQDs contains DPC at 1434 cm -1 The P=O bond stretching vibration and 1650cm -1The C=O bond absorption band at 1543 cm -1 The NH symmetric and symmetric stretching vibrations of the secondary amide at the Cm-HOPO-CQDs are also observed. -1 ) and -CH(3050cm -1 The above results show that DPC and Cm-HOPO were successfully modified on CQDs.

[0063] (2) Aggregation and fluorescence quenching behavior of Cm-HOPO-CQDs and DPC-CQDs after complexation with radionuclides

[0064] refer to Figure 5 a, Schematic diagram of the aggregation of Cm-HOPO-CQDs and DPC-CQDs after complexation with nuclides. Figure 5 b and 5c, in ultrapure water, the average particle size of Cm-HOPO-CQDs is 2.33nm, when 2mg of Cm-HOPO-CQDs and DPC-CQDs are added to 4mg / mL uranyl ion solution, the HOPO functional groups on the surface of functionalized CQDs quickly complex uranyl ions, and the hydrated particle size of the two complexes increases to about 1000nm. It can be seen that under the induction of nuclide ions, Cm-HOPO-CQDs and DPC-CQDs agglomerate when encountering nuclides, and have a certain absorption resistance potential.

[0065] refer to Figure 6 , the changes in fluorescence intensity of Cm-HOPO-CQDs and DPC-CQDs under the induction of gradient concentration of uranyl ions. It can be seen that when the uranyl ion concentration gradually increases from 0ppm to 400ppm, the fluorescence intensity of Cm-HOPO-CQDs and DPC-CQDs gradually decreases. The changes in hydrated particle size and fluorescence intensity can both reflect that uranyl ions induce Cm-HOPO-CQDs and DPC-CQDs to aggregate and cause fluorescence quenching.

[0066] (3) Decontamination experiments of Cm-HOPO-CQDs and DPC-CQDs

[0067] Prepare 2g / L uranium solution as simulated poison solution, 2% DTPA, 2% Cm-HOPO-CQDs and 2% DPC-CQDs solution as decontamination solution. Cut the pig skin into 1.2×1.2cm 2 Use a marker to mark a rectangle of 1×1 cm 2The size of the infected area was 200 μm, and the remaining area was sufficient for tweezers to grasp the skin. According to the disinfection delay time, the samples were divided into 60s and 2h groups. Each group was further divided into deionized water, 2% DTPA, 2% Cm-HOPO-CQDs and 2% DPC-CQDs groups according to the disinfection materials. Three parallel samples were set in each group.

[0068] (a) Characterization of decontamination efficiency of Cm-HOPO-CQDs and DPC-CQDs

[0069] Use a pipette to apply 20 μL of uranium solution with a concentration of 2g / L to the designated area of ​​the pig skin, and try to cover the infected area as completely as possible. Before and after the infection, the pig skin was placed in an electronic balance for weighing to obtain its accurate infection volume. After the infection, different solutions were disinfected according to the delay time. Deionized water, 2% DTPA, 2% Cm-HOPO-CQDs and 2% DPC-CQDs groups were all disinfected with 2mL of disinfectant, followed by rinsing with 3mL of deionized water. The disinfected solution was placed in a centrifuge tube, and the exact mass of the solution in the tube was calculated by weighing the difference between the empty tube and the centrifuge tube containing the mixed solution. The disinfectant was diluted about 1.5 times with 2% HNO3 solution and filtered with a 220nm water filter. Finally, the uranium concentration in each sample was determined by ICP-AES. The decontamination rate was calculated as follows:

[0070] Decontamination rate (%) = (uranium concentration in the test solution × total mass of the test solution) / (concentration of the poisoned uranium solution × mass of the poisoned uranium solution) × 100%.

[0071] like Figure 7 The schematic diagram of the decontamination experiment and the decontamination efficiency diagram of DTPA, Cm-HOPO-CQDs and DPC-CQDs show that the decontamination rates of the 2h group were lower than those of the 60s group, which was due to the fact that some uranium penetrated into the epidermis of the skin and then entered the dermis of the skin. In the 60s immediate decontamination group, the decontamination efficiencies of 2% Cm-HOPO-CQDs and 2% DPC-CQDs were 75.4% and 80.0%, respectively, which were better than deionized water (64.5%) and DTPA (74.3%). After a 2h delay in decontamination, the decontamination efficiency of 2% DPC-CQDs was 54.3%, slightly higher than 47.2% of Cm-HOPO-CQDs, while deionized water and 2% DTPA solution only decontaminated 25% and 27% of uranium, respectively. It can be seen that Cm-HOPO-CQDs and DPC-CQDs have significantly improved the decontamination efficiency of deionized water and DTPA.

[0072] (b) Particle size monitoring and absorption characterization of Cm-HOPO-CQDs and DPC-CQDs during decontamination

[0073] To monitor the aggregation behavior of Cm-HOPO-CQDs and DPC-CQDs during uranium decontamination, the above instant decontamination process was repeated, during which the rinse solution and deionized water were collected for DLS and TEM measurements, respectively. Figure 8 a-8d reflect the size and morphology of Cm-HOPO-CQDs and DPC-CQDs particles before and after uranium decontamination. It can be seen that during the decontamination process, most Cm-HOPO-CQDs and DPC-CQDs particles (2-4 nm) chelated uranyl ions and aggregated into loose aggregates of micrometer size (950-1720 nm, e.g. Figure 8 b and 8d). It is proved that Cm-HOPO-CQDs and DPC-CQDs have the function of chelating with uranium and aggregating into large particles during the decontamination process.

[0074] Then, the absorption resistance simulation experiment was carried out. The ex vivo pig skin was cut into 2×2.8 cm 2 and score each skin to form a 2×2.4cm rectangle. 2 The contaminated area and 2×0.4cm 2 400 μL of the solution containing 4 mg / L uranium, 4 mg / L uranium and 2 g / L DTPA, 4 mg / L uranium and 2 g / L Cm-HOPO-CQDs, and 4 mg / L uranium and 2 g / L DPC-CQDs were applied to the contaminated area of ​​each skin sample to simulate the decontamination residue. Figure 8 e. After 2 h, each skin was rinsed with 8 mL of deionized water, and the washing solution was collected for ICP-OES detection. Figure 8 As shown in Figure f, the Cm-HOPO-CQDs group and the DPC-CQDs group recovered 697.2 ng and 824.5 ng of uranium, respectively. The amount of uranium recovered by the DPC-CQDs group was 3.15 times and 1.44 times that of the deionized water group (261.8 ng) and the DTPA group (571.5 ng), respectively. The amount of uranium recovered by the Cm-HOPO-CQDs group was 2.59 times and 1.19 times that of the deionized water group (261.8 ng) and the DTPA group (571.5 ng), respectively, indicating that Cm-HOPO-CQDs and DPC-CQDs have significant anti-absorption capabilities.

[0075] (c) Dynamic monitoring of fluorescence intensity during decontamination of Cm-HOPO-CQDs and DPC-CQDs

[0076] Based on the fact that the fluorescence of Cm-HOPO-CQDs and DPC-CQDs can be quenched by uranyl ions, we prepared a 4 g / L uranium solution as a simulated poisoning solution and a 2 mg / mL Cm-HOPO-CQDs and DPC-CQDs decontamination solution. 2 Area, where 1×1cm is marked with a marker 2 The remaining area is used as the contaminated area, and the remaining area is convenient for picking up with tweezers.

[0077] Use a pipette to apply 80 μL of uranium solution to the designated area of ​​the pig skin. After 20 minutes, rinse with Cm-HOPO-CQDs and DPC-CQDs solutions, respectively. Rinse 4 times, 0.2 mL each time, collect the decontamination solution in four steps and test its fluorescence intensity to reflect the degree of uranium decontamination on the body surface. Comparison of the fluorescence intensity of Cm-HOPO-CQDs and DPC-CQDs after four rinses with the initial fluorescence intensity. Fig. 9 As shown in Figures 9a and 9b, it can be seen that the fluorescence intensity of the decontamination solution collected during the first decontamination was much lower than the initial fluorescence intensity. In the subsequent collection of decontamination solutions, the fluorescence intensity was in a gradual recovery process, and the fluorescence intensity of the decontamination solution collected for the fourth time was almost consistent with the fluorescence intensity of the initial decontamination solution. It can be proved that the fluorescence intensity changes of Cm-HOPO-CQDs and DPC-CQDs can be used as a means of real-time monitoring of the degree of decontamination, and have the prospect of integrated decontamination and detection functions.

[0078] The present invention utilizes the aggregation and fluorescence quenching characteristics of Cm-HOPO-CQDs and DPC-CQDs on uranium for the first time, and proposes a uranium skin decontaminant with anti-absorption and real-time monitoring functions. By modifying Cm-3,2-HOPO and DPC units with high chelating ability for uranium onto carbon quantum dots, new skin decontaminants Cm-HOPO-CQDs and DPC-CQDs were rationally designed and synthesized. The results of the skin decontamination experiment show that compared with deionized water and 2% DTPA solution, Cm-HOPO-CQDs and DPC-CQDs have significant decontamination advantages, and the longer the decontamination delay time, the more obvious the decontamination advantages of Cm-HOPO-CQDs and DPC-CQDs. In addition, the aggregation reaction of Cm-HOPO-CQDs and DPC-CQDs on uranyl ions effectively limits their penetration into the skin. Compared with deionized water, the anti-absorption capacity is 2.59 times and 3.15 times that of deionized water, respectively. In addition, the fluorescence quenching characteristics of Cm-HOPO-CQDs and DPC-CQDs in the presence of uranyl ions also realize the timely feedback of the decontamination effect. The aggregation and fluorescence quenching characteristics of Cm-HOPO-CQDs and DPC-CQDs solutions under uranium induction make them promising uranium decontamination agents with integrated absorption resistance and real-time monitoring functions, providing a new method for the design of skin decontamination products.

[0079] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A functionalized carbon quantum dot, characterized in that The structural formula is formula (1) or formula (2):

2. A method for preparing functionalized carbon quantum dots according to claim 1, characterized in that: It is formed by amidation of the amino group on the surface of the carbon quantum dot of formula (3) with the carboxyl group of the chelating agent ligand, wherein the chelating agent ligand is a compound of formula (4) or a compound of formula (5), and the reaction route is:

3. The method for preparing functionalized carbon quantum dots according to claim 2, characterized in that: The specific steps of the grafting are: adding an activator and a condensing agent to a chelating agent ligand solution under ice bath conditions, transferring to a constant temperature of 20-35° C., adding a carbon quantum dot solution, and reacting to obtain functionalized carbon quantum dots; Wherein, when the chelating agent ligand is a compound of formula (4), the reaction conditions are: adding palladium / carbon and removing the benzyl group on the hydroxypyridone under a hydrogen atmosphere.

4. The method for preparing functionalized carbon quantum dots according to claim 3, characterized in that: The activator is one or more of N-hydroxysuccinimide, 2,2-dihydroxymethylpropionic acid, and 1-hydroxybenzotriazole.

5. The method for preparing functionalized carbon quantum dots according to claim 3, characterized in that: The condensing agent is one or more of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N,N-dicyclohexylcarbodiimide and N,N'-diisopropylcarbodiimide.

6. The method for preparing functionalized carbon quantum dots according to claim 2, characterized in that: The preparation method of the carbon quantum dots is as follows: a citric acid monohydrate solution is mixed with a branched polyethyleneimine solution, and the mixture is reacted at 160-200° C. to obtain the carbon quantum dots.

7. The method for preparing functionalized carbon quantum dots according to claim 2, characterized in that: The preparation method of the compound of formula (5) is: S1, adding ethyl bromoacetate and a catalyst to an organic solution of a compound of formula (6), and reacting in an ice-water bath to obtain an intermediate of formula (7), the reaction route is: S2. The intermediate of formula (7) reacts with an acid in a boiling water bath to obtain the compound of formula (5).

8. The method for preparing functionalized carbon quantum dots according to claim 7, characterized in that: The catalyst is one or more of sodium bis(trimethylsilyl)amide, sodium methoxide, sodium ethoxide and quaternary ammonium base.

9. Use of the functionalized carbon quantum dots according to claim 1 in body surface radionuclide decontamination.

10. The use according to claim 9, characterized in that The nuclides are one or more of the actinide elements uranium, thorium, neptunium, plutonium, americium, the lanthanide elements europium, cerium, lanthanum, and the heavy metals mercury, chromium, and lead.

Citation Information

Patent Citations

  • Hydroxy-pyridone ligand and application thereof

    CN106928132A

  • Carbon quantum dot-poly N-isopropylacrylamide composite material and preparation method thereof

    CN102675565A

  • Carbon quantum dot modified by hydroxylpyridone compound, and preparation and application thereof

    CN109705029A

  • Preparation method and application of fluorescent viscose fiber

    CN114108314A

  • N-doped carbon quantum dot composite salix mongolica microcrystalline cellulose hydrogel as well as preparation method and application thereof

    CN117339579A